|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, October 08, 2018 ) This report covers the present scenario (with the base year being 2017) and the growth prospects of global Human Coagulation Factor VIII market for 2018-2023.
Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A.
North America is the largest consumption market of Human Coagulation Factor VIII, with sales market share nearly 46%. And the production market share of Human Coagulation Factor VIII is 58%. The manufacturers of Human Coagulation Factor VIII in North America have big and medium scale.
The second place is Europe, following North America with the sales market share of 36% and the production market share over 28%. Many European players have plants in USA due to rich plasma source. So there are a large number of Human Coagulation Factor VIIIs for import from other regions.
Asia is another important market of Human Coagulation Factor VIII, enjoying 10% production market share and 11% sales market share. Especially in China, the sales and price of Factor VIII are controlled by country, and the price in China is different from other regions.
Main players are from USA and Europe, like Baxter, Bayer, and they have many plants in other regions. China also can supply Human Coagulation Factor VIII, but the products are mainly consumed in China.
Market competition is intense. Baxter, Bayer, CSL, Pfizer, Grifols, etc. are the leaders of the industry, and hold key technologies, with high-end customers, have been formed in the monopoly position in the industry. However, with further expanding market, there will be more manufactures in the future.
Over the next five years, this report projects that Human Coagulation Factor VIII will register a 2.8% CAGR in terms of revenue, reach US$ 8770 million by 2023, from US$ 7440 million in 2017.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Coagulation Factor VIII market by product type, application, key manufacturers and key regions.
To calculate the market size, this report considers value and volume generated from the sales of the following segments:
Segmentation by product type:
Recombinant Factor VIII
Plasma-derived Factor VIII
Segmentation by application:
Hemophilia A
Spontanous / Trauma
Surgical
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Shire (Baxter)
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Human Coagulation Factor VIII consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Human Coagulation Factor VIII market by identifying its various subsegments.
Focuses on the key global Human Coagulation Factor VIII manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Human Coagulation Factor VIII with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Human Coagulation Factor VIII submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
To get Free Sample or to Buy this report at discounted price visit: https://www.nxtgenreports.com/market-research-reports/2018-2023-global-human-coagulation-factor-viii
If you have any special requirements, kindly Contact Us and we will offer you the report as you want.
About NxtGen Reports: NxtGen Reports delivers strategic market research reports, industry analysis, business research and forecasts on product, services and companies. We understand the need of our customers and keep our market research reports up to date. Our reports are very well organized enabling our customers to identify and get access easily. We also offer customized discounts based on your expectations.
Contact Information:
Madhuri Vetal
NxtGen Reports
Email: sales@nxtgenreports.com
Phone: +918551022388
More Report at: https://www.nxtgenreports.com/market-research-reports
NxtGen Reports
Madhuri Vetal
+918551022388
sales@nxtgenreports.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
